Overexpression of DGKI in Gastric Cancer Predicts Poor Prognosis

Chao Huang, Jiefeng Zhao, Chen Luo and Zhengming Zhu*

Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

Background: Diacylglycerol kinase iota (DGKI) is overexpressed in a variety of cancers and is associated with poor prognosis in colon cancer. This study evaluated the prognostic value of DGKI in gastric cancer (GC) using data from The Cancer Genome Atlas (TCGA).

Methods: RNA sequencing results and clinical data of gastric adenoma and adenocarcinoma samples were obtained from the TCGA database (https://portal.gdc.cancer.gov). The Wilcoxon or Kruskal–Wallis test and logistic regression were used to analyze the relationship between DGKI and the clinicopathological characteristics of GC patients. Univariate Cox regression and Kaplan-Meier analysis were used to analyze the clinicopathological characteristics of GC patients and the relationship between DGKI and overall survival time, and multivariate Cox regression analysis was used to identify independent risk factors affecting the prognosis of GC patients. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset.

Results: DGKI was overexpressed in gastric tumors and was related to poor prognosis (p = 0.003). Overexpression of DGKI in GC was significantly correlated with high grade (OR = 1.71 for G3 vs. G2), stage (OR = 2.08 for II vs. I) and T classification (OR = 4.64 for T4 vs. T1; OR = 3.99 for T3 vs. T1; OR = 3.37 for T2 vs. T1) (all p < 0.05). DGKI (OR = 7.34; p = 0.000) was an independent risk factor affecting the survival of GC patients. The MAPK signaling pathway was differentially enriched with DGKI overexpression.

Conclusion: DGKI overexpression may be a potential molecular marker for poor prognosis in GC. The MAPK signaling pathway may be one of the key pathways related to DGKI regulation in GC.

Keywords: gastric cancer, DGKI, TCGA, prognosis, GSEA

INTRODUCTION

Gastric cancer (GC) is a common malignant tumor of the digestive system, and its mortality rate ranks third (1). After radical gastrectomy, the 5-year survival rate of early gastric cancer can reach more than 90% (2, 3), but that of advanced gastric cancer is <10% (4). Postoperative recurrence is the main cause of the short survival time in patients with GC. Adjuvant chemotherapy can prevent recurrence and significantly improve the survival rate (5). Therefore, early identification and adjuvant chemotherapy are crucial for improving the survival of patients with advanced gastric cancer. Metabolic reprogramming has become a new marker of cancer development, and its success has confirmed that cancer is a metabolic disease (6). Recent studies have found that mitochondrial dysfunction, signaling, fatty acid metabolism, and mitochondrial autophagy are also related to...
tumor growth (7, 8). Diacylglycerol kinase iota (DGKI) is a member of the type IV diacylglycerol kinase subfamily. Diacylglycerol kinases regulate the intracellular concentration of diacylglycerol by phosphorylating, producing phosphatidic acid (PA) (9). Studies have shown that PA can regulate some signaling proteins, including protein kinases and phosphatases, and can mediate growth factors to induce mitosis of cells (10). The Mitogen-activated protein kinase (MAPK) signaling pathway is an important pathway for extracellular signals regulating cell mitosis, and Raf protein transfer from the cytoplasm to the membrane and activation by Ras or other kinases are key steps in the activation of this signaling pathway (11). Moreover, studies have indicated that Raf can directly bind to PA (12), so an increase in PA content promotes the translocation of the Raf protein to the cell membrane and activates the MAPK signaling pathway. Recently, studies (13) showed that DGKI was overexpressed in a variety of cancers and was associated with poor prognosis in colon cancer. However, a correlation between DGKI and the prognosis of GC has not been reported. Therefore, the purpose of this study was to evaluate the prognostic value of DGKI expression in GC based on data obtained from The Cancer Genome Atlas (TCGA) and to conduct gene set enrichment analysis (GSEA) to identify the signaling pathways related to DGKI regulation in GC.

MATERIALS AND METHODS

Data Extraction and Processing

RNA sequencing results from 373 tissues to 348 human gastric adenoma and adenocarcinoma samples were obtained from the TCGA database (https://portal.gdc.cancer.gov). A Perl language (http://www.perl.org/) script was used to combine the RNA-seq results of 30 normal samples and 343 cancer samples into a single matrix file. The Ensembl database (http://www.ensembl.org/index.html) and a Perl script were then used to convert the Ensembl ID in the matrix file to the gene name. In addition, 406 sets of clinical data were downloaded, and then Perl language scripts were used to organize and extract relevant clinical data.

GSEA

GSEA is used to assess whether a predefined set of genes show statistically significant, concordant differences between two biological states (14). To identify the potential mechanism by which DGKI expression affects the prognosis of gastric cancer patients, GSEA was to first generate an ordered gene list based on the correlation between all genes and DGKI expression. GSEA was then used to elicit the significant survival differences observed between the high and low DGKI groups. Gene set permutations were conducted 1,000 times for each analysis, and the expression level of DGKI was used as the phenotypic label. Gene sets with normalized (NOM) \( p < 0.05 \) and false discovery rates (FDRs) < 0.05 were defined as significantly enriched.

Statistical Analysis

The Wilcoxon test was used to analyze the expression level of DGKI in tumor samples and normal samples. Kaplan-Meier analysis was used to compare the survival times between the DGKI high expression group and the DGKI low expression group, and the \( p \)-value was calculated by a log-rank test. The cut-off value for DGKI expression was determined by its median value. The Wilcoxon or Kruskal–Wallis test and logistic regression were used to analyze the relationship between DGKI and clinicalopathological characteristics. Univariate Cox regression analysis was used to analyze the clinicalopathological characteristics of GC patients and the relationship between DGKI and overall survival time. The factors affecting the survival of GC patients in univariate Cox regression analysis were analyzed by multivariate Cox regression to find independent risk factors affecting the prognosis of GC patients. A \( p < 0.05 \) was considered statistically significant. All statistical analyses were performed using R (version x64 3.5.1).

RESULTS

Clinical Characteristics of Patients

We identified some genes that were related to the prognosis of GC patients and can be used as independent risk factors affecting the prognosis of GC patients in the data downloaded from the TCGA database (Supplementary Tables 1, 2). Next, we further analyzed DGKI. The clinical data of 406 patients were downloaded from the TCGA database, and the patient's age, sex, histological grade, stage, TNM stage, survival time, and survival status were extracted. After deleting samples with incomplete clinical data, a total of 292 patients were obtained for further analysis (Table 1).

Relationship Between the Expression of DGKI and Survival

The difference in expression of DGKI between gastric tumors and normal tissues was statistically significant (\( p < 0.001 \)), indicating that DGKI was overexpressed in gastric tumors (Figure 1). The difference in survival time between patients with high expression of DGKI and those with low expression of DGKI was statistically significant (\( p = 0.003 \)), showing that GC patients with high expression of DGKI had poor prognosis (Figure 2).

Association Between DGKI Expression and Clinical Characteristics

We analyzed 292 GC samples with DGKI expression and acquired clinical data. Histological grade (\( p < 0.001 \)), stage (\( p = 0.006 \)), and T classification (\( p < 0.001 \)) were related to the expression level of DGKI (Figure 3). Logistic regression analysis was performed after grouping according to the median expression of DGKI. The results showed that overexpression of DGKI in GC was significantly correlated with high grade (OR = 1.71 for G3 vs. G2), stage (OR = 2.08 for II vs. I) and T classification (OR = 4.64 for T4 vs. T1; OR = 3.99 for T3 vs. T1; OR = 3.37 for T2 vs. T1) (all \( p < 0.05 \)) (Table 2). These results suggest that GC patients with high DGKI expression are more likely to have advanced gastric cancer than GC patients with low DGKI expression.
TABLE 1 | Clinical characteristics of patients with gastric cancer.

|                        | n (%)  |
|------------------------|--------|
| **Age**                |        |
| ≤65 years              | 129 (44.18) |
| >65 years              | 163 (55.82) |
| **Sex**                |        |
| Male                   | 176 (60.27) |
| Female                 | 116 (39.73) |
| **Histological grade** |        |
| G1                     | 5 (1.71) |
| G2                     | 101 (34.59) |
| G3                     | 186 (63.70) |
| **Stage**              |        |
| I                      | 41 (14.04) |
| II                     | 94 (32.19) |
| III                    | 126 (43.15) |
| IV                     | 31 (10.62) |
| **T classification**   |        |
| T1                     | 15 (5.14) |
| T2                     | 61 (20.89) |
| T3                     | 142 (48.63) |
| T4                     | 74 (25.34) |
| **M classification**   |        |
| M0                     | 273 (93.49) |
| M1                     | 19 (6.51) |
| **N classification**   |        |
| N0                     | 92 (31.51) |
| N1                     | 76 (26.03) |
| N2                     | 65 (22.26) |
| N3                     | 59 (20.20) |
| **Survival status**    |        |
| Death                  | 102 (34.93) |
| Survival               | 190 (65.07) |

**Univariate and Multivariate Cox Regression Analysis**

Univariate Cox regression analysis showed that the factors affecting the survival of GC patients were age ($p = 0.005$), stage ($p = 0.000$), T classification ($p = 0.045$), M classification ($p = 0.017$), N classification ($p = 0.013$), and DGKI ($p = 0.015$) (Table 3). Multivariate Cox regression analysis of the above factors found that age (OR = 1.05; $p = 0.000$) and DGKI (OR = 7.34; $p = 0.000$) were independent risk factors affecting the survival of patients with GC (Table 3 and Figure 4).

**GSEA Identifies DGKI-Related Signaling Pathways**

We performed GSEA of the high and low DGKI expression datasets to identify differentially activated signaling pathways in GC. GSEA was performed using the MSigDB collection (c2.cp.kegg.v7.0.symbols.gmt). We screened differentially enriched pathways associated with the DGKI high expression phenotype with FDR < 0.05 and NOM $p < 0.05$ cut-offs (Table 4). Pathways related to ECM receptor interactions, focal adhesion, calcium signaling, TGF-beta signaling, MAPK signaling, Hedgehog signaling, cell adhesion molecules (CAMs), adherens junctions, and cancer were differentially enriched with the DGKI high expression phenotype (Figure 5).
Huang et al. DGKI Overexpression Predicts Poor Prognosis

FIGURE 3 | Association between DGKI expression and clinicopathologic characteristics, including grade, stage, and T classification.

TABLE 2 | DGKI expression associated with clinical pathological characteristics (logistic regression).

| Clinical characteristics | Total (n) | Odds ratio in DGKI expression | p-value |
|--------------------------|----------|------------------------------|---------|
| Age (>65 years vs. ≤65 years) | 341 | 0.96 (0.63–1.48) | 0.865 |
| Sex (male vs. female) | 406 | 0.83 (0.54–1.29) | 0.410 |
| Histological grade (G3 vs. G2) | 328 | 1.71 (1.09–2.68) | 0.019 |
| Stage (I vs. II) | 152 | 2.08 (1.05–4.23) | 0.039 |
| T classification (T1 vs. T4) | 104 | 4.64 (154–17.32) | 0.011 |
| (T3 vs. T1) | 176 | 3.99 (1.36–14.50) | 0.018 |
| (T2 vs. T1) | 93 | 3.37 (1.10–12.67) | 0.046 |
| M classification (M0 vs. M1) | 327 | 0.92 (0.39–2.15) | 0.841 |
| N classification (N0 vs. N3) | 167 | 1.62 (0.87–3.07) | 0.132 |
| (N2 vs. N0) | 173 | 0.94 (0.51–1.72) | 0.840 |
| (N1 vs. N0) | 191 | 0.97 (0.55–1.71) | 0.907 |

TABLE 3 | Univariate and multivariate analysis of the correlation of DGKI expression with overall survival among patients with gastric cancer.

| Clinicopathologic variable | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|---------------------|
|                            | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age (1.03 (1.01–1.05) | 0.005 | 1.05 (1.02–1.07) | 0.000 |
| Sex (1.51 (0.99–2.31) | 0.059 | 1.62 (0.87–3.07) | 0.132 |
| Histological grade (1.44 (0.83–1.83) | 0.269 | 0.94 (0.51–1.72) | 0.840 |
| Stage (1.53 (1.21–1.94) | 0.000 | 1.58 (1.0–2.50) | 0.052 |
| T classification (1.29 (1.01–1.64) | 0.045 | 0.97 (0.69–1.35) | 0.838 |
| M classification (2.23 (1.16–4.30) | 0.017 | 2.0 (0.84–4.73) | 0.116 |
| N classification (1.25 (1.05–1.50) | 0.013 | 1.07 (0.82–1.39) | 0.625 |
| DGKI (3.29 (1.26–8.57) | 0.015 | 7.34 (2.54–21.18) | 0.000 |

DISCUSSION

Metabolic reprogramming has become a new marker of cancer development and its success has confirmed that cancer is a metabolic disease (6). TP53 (tumor protein p53) is the most common mutated gene in human cancer, with more than half of tumors accompanied by TP53 changes (15). Studies have shown that TP53 controls various metabolic pathways, including glycolysis, lipid metabolism and mitochondrial function (16, 17). DGKI regulates the concentration of intracellular diacylglycerin through phosphorylation to produce phosphatidic acid (9). Moreover, studies have found that PA can regulate some signaling proteins, including protein kinases and phosphatases, and it can mediate growth factors to induce mitosis in cells (10). Previous studies (9) showed that DGKI was expressed in the retina and brain, suggesting that it may play an important role in retinopathy. In addition, Ohanian and Ohanian (18) showed that DGKI plays a role in regulating the contraction of vascular smooth muscle which plays a role in hypertension. Recently, Etcheverry et al. (19) indicated that DGKI methylation status was associated with the prognosis of patients with glioblastoma. Penrose et al. (13) demonstrated that DGKI was overexpressed in a variety of cancers and was associated with poor prognosis of colon cancer. Our study found that DGKI was overexpressed in gastric tumors and was associated with a poor prognosis for patients. Meanwhile, overexpression of DGKI in GC was significantly correlated with high grade, stage and T classification. In addition, multivariate Cox analysis showed that DGKI was an independent risk factor affecting the survival of GC patients.

To further study the function of DGKI in GC, we performed GSEA. GSEA found that pathways related to ECM receptor interactions, focal adhesion, calcium signaling, TGF-beta signaling, MAPK signaling, Hedgehog signaling, cell adhesion molecules (CAMs), adherens junctions, and cancer were differentially enriched with the DGKI high expression phenotype. The MAPK pathways have different signaling cascades; the Ras-Raf-Mek-extracellular signal-regulated kinases 1 and 2 pathway, one of the MAPK pathways, is one of the most dysregulated pathways in human cancer and it regulates a variety of key cellular functions, including proliferation, growth, and aging (20). The Raf protein continuously activates the MAPK pathway, causing abnormal differentiation, proliferation and apoptosis, as well as the development of cancer (21). Ghosh et al. (12) showed that Raf can bind directly to PA, such that an increase in PA content promotes the translocation of the Raf protein to the cell membrane and activates the MAPK signaling pathway. We performed GSEA and found that the
MAPK signaling pathway was differentially enriched with DGKI overexpression. However, the regulatory mechanism needs to be further elucidated.

In addition, several studies have indicated that the AMP-activated protein kinase (AMPK) and MAPK3/1 pathways may be biological predictors and beneficial targets for cancer treatment using metabolic alterations (22, 23). Kim et al. (24) reported that AMPK may inhibit the MAPK3/1 pathway; the inhibition of AMPK by expressing a dominant-negative form potentiates MAPK3/1 activation under glucose deprivation in colon cancer cells. However, Kim et al. (25) also showed that the effects of AMPK activation and the association between the AMPK and MAPK3/1 pathways need to be further elucidated to improve the treatment strategies for human cancer. We performed GSEA of the high and low DGKI expression datasets to identify differentially activated signaling pathways in GC, and did not find that the AMPK pathway was differentially enriched in the DGKI high expression phenotypes. Therefore,
Huang et al. | DGKI Overexpression Predicts Poor Prognosis

FIGURE 5 | Enrichment plots from gene set enrichment analysis (GSEA). GSEA results showing differential enrichment of genes related to ECM receptor interaction, focal adhesion, calcium signaling pathway, TGF-beta signaling pathway, MAPK signaling pathway, Hedgehog signaling pathway, cell adhesion molecules (CAMs), adherens junction, and pathways in cancer in gastric cancer with high DGKI expression.

the correlation between DGKI and AMPK pathway needs to be further studied, which may also be a direction of our future research. In conclusion, DGKI overexpression may be a potential molecular marker for poor prognosis in GC. The MAPK signaling pathway may be one of the key pathways related to DGKI regulation in GC. However, it is necessary to carry out further experimental verification to prove the biological function of DGKI.

DATA AVAILABILITY STATEMENT

The datasets generated for this study can be found in the https://portal.gdc.cancer.gov.

AUTHOR CONTRIBUTIONS

CH and ZZ: designed the study. CH and JZ: collected data. CH and CL: analyzed the data. CH: wrote the manuscript with
contribution from all authors. ZZ: provided critical comments for this paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (Grant Number: 81560389) and Key Research and Development Program of Jiangxi Province (Grant Number: 2018BBG70015).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.00320/full#supplementary-material

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492
2. Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med. (2015) 12:355–61. doi: 10.7497/j.isnn.2095-3941.2015.0054
3. Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. (2011) 14:301–16. doi: 10.1007/s10120-011-0085-6
4. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterra MM, et al. Treatment of gastric cancer. World J Gastroenterol. (2014) 20:1635–49. doi: 10.3748/wjg.v20.i17.1635
5. Fujitani K, Tamura S, Kimura Y, Matsuuya J, Inamura H, Yamamoto K, et al. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Gastric Cancer. (2019) 23:520–30. doi: 10.1007/s10120-019-01023-w
6. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. (2016) 2:e1600200. doi: 10.1126/sciadv.1600200
7. Suliman HB, Piantadosi CA. Mitochondrial quality control as a therapeutic target. Pharmacol Rev. (2016) 68:20–48. doi: 10.1124/pr.115.011502
8. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. (2016) 166:555–66. doi: 10.1016/j.cell.2016.07.002
9. Ding L, Traer E, McIntyre TM, Zimmerman GA, Prescott SM. The cloning and characterization of a novel human diacylglycerol kinase, DGKiota. J Biol Chem. (1998) 273:32746–52. doi: 10.1074/jbc.273.49.32746
10. Buckland AG, Wilton DC. Anionic phospholipids, interfacial binding and characterization of novel human diacylglycerol kinases and their relevance to hypertension. J Hum Hypertens. (1999) 13:35–40. doi: 10.1038/sj.jhh.1001139
11. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vouwen KH. Raf kinases in cancer - transformation and drug resistance. Biochim Biophys Acta. (2011) 1806:64–77. doi: 10.1016/j.bbamcr.2010.10.001
12. Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem. (1996) 271:8472–80. doi: 10.1074/jbc.271.14.8472
13. Penrose HM, Heller S, Cable C, Nakhoul H, Ungerleider N, Baddoo M, et al. In colonic rho0(0) (rho0) cells reduced mitochondrial function mediates transcriptional alterations associated with cancer. Oncogene. (2017) 4:189–98. doi: 10.1038/oncogenesis.2016.386
14. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. (2005) 102:15545–50. doi: 10.1073/pnas.0506580102
15. Muller PA, Vouwen KH. p35 mutations in cancer. Nat Cell Biol. (2013) 15:2–8. doi: 10.1038/ncb2641
16. Choudhury AR, Singh KK. Mitochondrial determinants of cancer health disparities. Semin Cancer Biol. (2017) 47:125–46. doi: 10.1016/j.semcancer.2017.05.001
17. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vouwen KH. Mitochondrial quality control as a therapeutic target. Oncogene. (2013) 32:1659–77. doi: 10.1038/onc.2012.588
18. Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, et al. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide. PLoS One. (2014) 9:e104455. doi: 10.1371/journal.pone.0104455
19. McCartney JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Wang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. (2007) 1773:1263–84. doi: 10.1016/j.bbadis.2006.10.001
20. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. (2011) 30:3477–88. doi: 10.1038/onc.2011.160
21. Wang W, Guan KL. AMP activated protein kinase and cancer. Acta Physiol. (2009) 196:55–63. doi: 10.1111/j.1748-1716.2009.01980.x
22. Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev Res. (2009) 2:301–9. doi: 10.1158/1940-6207.CAPR-08-0166
23. Kim MJ, Park JJ, Yun H, Kang I, Choe W, Kim SS, et al. AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma. J Biol Chem. (2010) 285:14617–27. doi: 10.1074/jbc.M109.085456
24. Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ, Oh SY, et al. Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer. Oncology. (2011) 85:78–85. doi: 10.1159/000351234

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Huang, Zhao, Luo and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**